GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory that will use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new medicines.
